Welcome to vnonline.co.uk

vnonline.co.uk provides the veterinary nursing profession with the latest news and industry developments, as well as events, resources, learning materials and careers.

Our website is dedicated to veterinary nurses and we strive to provide a platform where you can voice and explore your interests.

Not a member yet? Sign up for free!

Register for free with vnonline.co.uk to gain unlimited access to news, resources, jobs and much more!



Click here to become a member







Log in to vnonline

Forgot your password?

Posted: 20th January 2020

Injectable omeprazole ‘can be used within rules’, BHA confirms
"Long-acting injectable omeprazole has become an important treatment option for horses with gastric disease" - Dr Mike Hewetson. 

Vets had been previously advised against using the drug owing to traces of testosterone

The British Horseracing Authority (BHA) has announced that injectable omeprazole, manufactured by Bova UK, can now be used in racehorses ‘within rules’.

Veterinary professionals had previously been advised against possessing, using or administering the drug in racehorses after small traces of testosterone were discovered in a batch of the product last year.


Although independent experts said there could be no adverse effects on equine health or equestrian sport, BOVA took immediate action to identify and eliminate the ingredient that contained the testosterone.


In September 2019, the product was declared free of testosterone and has since continued to be used in Australian racehorses after guidance from Racing NSW. Tests on multiple samples of injectable omeprazole ahead of sale have also since demonstrated the product to be free of testosterone. 


Dr Mike Hewetson from the Royal Veterinary College explained: “Long-acting injectable omeprazole has become an important treatment option for horses with gastric disease, particularly those affected by glandular gastric disease.”

A recent blind clinical trial of Bova’s injectable omeprazole found that healing rates for both glandular and squamous gastric disease were four times higher with injectable omeprazole than with a registered oral product.




Become a member
or log in to add this story to your CPD history